NDAORALGRANULEPriority Review
Approved
Apr 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
FLAVORED COLESTID (colestipol hydrochloride) by Pfizer is clinical pharmacology cholesterol is the major, and probably the sole precursor of bile acids. Approved for hypertension. First approved in 1977.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Flavored Colestid (colestipol hydrochloride) is an oral anion exchange resin indicated for hypertension that works by binding bile acids in the intestine and preventing their reabsorption, leading to increased cholesterol oxidation and reduced LDL cholesterol levels. It is administered as a granule formulation and acts through a nonsystemic mechanism in the gastrointestinal tract.
LOE Approaching
Product approaching loss of exclusivity with minimal linked career opportunities, signaling a contracting commercial footprint and likely reduced team investment.
Mechanism of Action
CLINICAL PHARMACOLOGY Cholesterol is the major, and probably the sole precursor of bile acids. During normal digestion, bile acids are secreted via the bile from the liver and gall bladder into the intestines. Bile acids emulsify the fat and lipid materials present in food, thus facilitating…
Worked on FLAVORED COLESTID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.